ClearMind Biomedical

ClearMind Biomedical is a medical device company founded in 2014 with Y Combinator backing that develops micro-invasive neurosurgical technology for treating intracerebral hemorrhage (ICH) and related brain injuries. Its flagship Neuroblade System is an FDA 510(k)-cleared all-in-one neuroendoscopy platform integrating visualization, aspiration, powered morcellation, irrigation, and cautery in a single sterile kit requiring only a 6.5mm channel through the skull. The company's 'One Doctor, One Hour' mission targets hemorrhagic stroke — the deadliest form of stroke with a 36-60% mortality rate — enabling a single surgeon to complete critical procedures in one hour, even at small regional hospitals. ClearMind has received additional regulatory approvals in Thailand and markets its Neuroblade System globally through distributor partnerships including exclusive U.S. distributor Sutter Medical Technologies.